Defining an acceptable period of time from melanoma biopsy to excision

Dermatology Reports

Volumn 4, Issue 1, 2012, Pages

  Huff, Laura S ^a   Chang, Caroline A ^b   Thomas, Jacob F ^c   Cook Shimanek, Margaret ^d   Blomquist, Paul ^d   Konnikov, Nellie ^e   Dellavalle, Robert P ^a,c,e  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c Food Science and Human Nutrition   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Melanoma; Melanoma survival; Surgical interval; Time factors; Treatment time

Indexed keywords

ARTICLE; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MELANOMA; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SKIN BIOPSY; SKIN SURGERY; TREATMENT INDICATION; COMPARATIVE STUDY; HOSPITAL DEPARTMENT; MEDICAL PARAMETERS; MELANOMA SKIN CANCER; PRACTICE GUIDELINE; SURGICAL INTERVAL; THERAPY DELAY; TIME;

EID: 84859506870     PISSN: 20367392     EISSN: 20367406     Source Type: Journal    
DOI: 10.4081/dr.2012.e2     Document Type: Article

References (18)

1. American Cancer Society. Cancer Facts & Figures 2011. Available from: http://www.cancer.org/Research/CancerFactsFigures/index
2. National Cancer Institute. Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. Available from: seer.cancer.gov/publications/aya/aya_mono_complete.pdf
3. National Cancer Institute. SEER Cancer Statistics Review, 1975-2006. Available from: http://seer.cancer.gov/csr/1975_2006/
4. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58 71-96.
5. Mouawad R, Sebert M, Michels J, et al. Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol 2010;74:27-39.
6. Brenner S, Tamir E. Early detection of melanoma: the best strategy for a favorable prognosis. Clin Dermatol 2002;20: 203-11.
7. Yao K, Balch G, Winchester DJ. Multidisciplinary treatment of primary melanoma. Surg Clin North Am 2009;89: 267-81.
8. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48.
9. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
10. Carpenter S, Pockaj B, Dueck A, et al. Factors influencing time between biopsy and definitive surgery for malignant melanoma: do they impact clinical outcome? Am J Surg 2008;196:834-43.
11. Coldiron B. No evidence to support delay in excision of malignant melanoma. Arch Dermatol 2000;136:1269-71.
12. Doherty V, MacKie R. Reasons for poor prognosis in British patients with cutaneous malignant melanoma. Br Med J (Clin Res Ed) 1986;292:987-9.
13. Richards MA, Westcombe AM, Love SB, et al. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet 1999;353:1119-26.
14. Richards MA, Smith P, Ramirez AJ, et al. The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer 1999;79: 858-64.
15. Korsgaard M, Pedersen L, Sørensen HT, Laurberg S. Delay of treatment is associated with advanced stage of rectal cancer but not of colon cancer. Cancer Detect Prev 2006;30:341-6.
16. McKenna D, Lee R, Prescott R, Doherty V. The time from diagnostic excision biopsy to wide local excision for primary cutaneous malignant melanoma may not affect patient survival. Br J Dermatol 2002;147: 48-54.
17. Epstein E, Bragg K, Linden G. Biopsy and prognosis of malignant melanoma. JAMA 1969;208:1369-71.
18. Pacifico M, Pearl R, Grover R. The UK Government two-week rule and its impact on melanoma prognosis: an evidencebased study. Ann R Coll Surg Engl 2007;89:609-15.